# CBER official overruled review team’s rejection of new Replimune melanoma drug

> **Newsylist Open Intelligence Dossier** · First detected: 2026-09-03 19:29 UTC · Category: Business · Sources: 4 · Current Velocity: 2

## Multi-Source Evidence Table
| Source Outlet | Headline | Published (UTC) | Verification URL |
|---|---|---|---|
| Dermatology Times | Dermatology Times Monthly FDA & Pipeline Review: August 2026 | 2026-09-02 16:02 | [Source Link](https://news.google.com/rss/articles/CBMimwFBVV95cUxOUUFybXpINnUxUWNLbnBWc0hBRjhxb3lkN19PLXE1QVpvbWIyMVplODljTC0wdU1SazVSOVVDNTNhNS1Zb09vLVdrNFBMREFVRWlFaXZkdHpGZXZoN1hPUmNhaG92a3ZNQ2tiYUprSWxraTJZeHZlRW5ZZExUaFliT0lQclVrYmRhN0U5X0stdVR4NUlEQmtmTmJCVQ?oc=5) |
| OncLive | August Roundup of FDA Approvals in Oncology: Daraxonrasib Highlights 5 Decisions to Know | 2026-09-02 16:02 | [Source Link](https://news.google.com/rss/articles/CBMitwFBVV95cUxPeGQ4NjlMV2hINW1nZmlNSlYtMXpxQy1NY2dHME9rb3JYdVNuVUFHbEVrU2lnbHBxaVJnSkIzSlhSUFh0UEFvQjRmRlVVTkd2NHRRd3dqejRwcno4Y0tEcFUtRDdRY2pDb25hX3YySmNIa2VfVW9TVTducVRTTDJ2b2Fzc2RvTnZyNXZBMFZXOTF5eWNhUzh0S0pEcnN6b2sxR3ZKdUtjbVZibElpR2ViNVg1bTJiTkk?oc=5) |
| Fierce Pharma | FDA files reveal lingering concerns, contrasting views behind Replimune melanoma nod | 2026-09-02 16:02 | [Source Link](https://news.google.com/rss/articles/CBMixAFBVV95cUxOdzh0TG1fVTFyNXRQLXppWkItQkN2ZzU3cTRKOV8xUWhfLTZRVkhTNE1fbUpQMXZIaGlkaHhFdUdPYXJZSUNTS1hnYnpfM0JTUXJ2V2lkSDRIbU1xVk0wWjM4SElERWpEWDVzNGhlajBSV0VFRXdkWVJWczVXZldYZTh3cjBYS3g5SmdsMW5QcEhyT2ZkTWJqWm0zc29IM0xlOWc1YThvQXhIanZYd0JoWU9HUEdlaXRUb1Q0SERKa0NJTG1W?oc=5) |
| Endpoints News | CBER official overruled review team’s rejection of new Replimune melanoma drug | 2026-09-02 16:02 | [Source Link](https://news.google.com/rss/articles/CBMiowFBVV95cUxNc05IWmNsX25YdlRoU0Nya0dEZjBqNDNuS2xLSmRBYzNaV3psN3dMRDBUTVpXNndrVldUTVVjRVdfLURSVjhvZ0VJbnZWa1ItRDBOQTFzQi1ua2Fqb0hPZ0lZMWY1dHZ3UjJ6UHpSa2tzM3VpbjA2Vk5OZm1kbGhhdFAzZEdyRVVmVTlmUWdrZ2NQRU5OQjBpVnlYSUFxZTJkS0lZ?oc=5) |

---
*Canonical Source: https://www.newsylist.com/trend/2026-09-03/cber-official-overruled-review-team-s-rejection-of-new-replimune-melanoma-drug*
*Synthesized by Newsylist Open Intelligence Engine under E-E-A-T journalistic standards.*